CMS Seeks To Exclude 340B From Inflation Rebates, Factor Negotiated Prices In ASP

By Gabrielle Wanneh / July 15, 2025 at 6:30 PM

CMS is proposing a new claims-based approach to ensure units of prescription drugs sold under the 340B drug discount program are not included in Medicare Part D inflation-related rebate calculations at the start of next year, and the agency also plans to factor negotiated drug prices into average sales price (ASP) calculations.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.